Large cell cancer
Drug research and approvals for large cell cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 349 studies of large cell cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 349
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Newest posted first, of 349 recruiting on ClinicalTrials.gov ↗
- Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment…NCT07934537 · Phase 4 · Shanghai Tongji Hospital, Tongji University School of Medicine · starts Oct 30, 2025
- Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and…NCT07908888 · Phase 4 · The First Hospital of Jilin University · starts Oct 15, 2026
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or…NCT07892027 · Phase 2 · University of Michigan Rogel Cancer Center · starts Nov 10, 2026
- Prospective ctDNA Testing in Large B-Cell LymphomaNCT07878351 · Not reported · Peking University People's Hospital · starts Oct 15, 2026
- Proton Therapy for Mediastinal Lymphoma (PROMLY)NCT07817641 · Not applicable · Copenhagen University Hospital, Rigshospitalet · starts May 1, 2026
- A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus…NCT07808827 · Phase 3 · Shanghai Junshi Bioscience Co., Ltd. · starts Oct 8, 2026
- A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory…NCT07788118 · Phase 1 / Phase 2 · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts Sep 1, 2026
- CD38 Targeted -PET/ CT for Multiple MyelomaNCT07782944 · Not applicable · Guilin Medical University, China · starts Jul 7, 2026
- Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCLNCT07778212 · Not applicable · The First Affiliated Hospital of Xiamen University · starts Aug 30, 2026
Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications
Approved 1
- PemetrexedThymidylate synthase inhibitor
Phase 3 4
- CarboplatinDNA inhibitor
- PaclitaxelTubulin inhibitor
- ErlotinibEpidermal growth factor receptor erbB1 inhibitor
- FigitumumabInsulin-like growth factor I receptor antagonist
Phase 2 12 of 13
- CisplatinDNA inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- DurvalumabProgrammed cell death 1 ligand 1 inhibitor
- DocetaxelTubulin inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- VinorelbineTubulin inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- PegfilgrastimGranulocyte colony stimulating factor receptor agonist
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- MK-2206Serine/threonine-protein kinase AKT inhibitor
- CixutumumabInsulin-like growth factor I receptor antagonist
Phase 1 or earlier 1
- VeliparibPARP 1, 2 and 3 inhibitor
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA